VEREGEN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VEREGEN (VEREGEN).
Veregen (sinecatechins) is a topical botanical drug product containing a defined mixture of catechins from green tea leaves. Its exact mechanism of action is unknown, but it is thought to involve immunomodulatory and antiviral activities, including inhibition of cellular proliferation and induction of apoptosis in HPV-infected cells.
| Metabolism | Not extensively metabolized; based on minimal systemic absorption after topical application, metabolism is not fully characterized. |
| Excretion | Following topical application, systemic absorption of sinecatechins is minimal. Unabsorbed drug is eliminated primarily in feces. Renal excretion of absorbed drug is negligible (<1%). |
| Half-life | The terminal elimination half-life cannot be accurately determined due to minimal systemic absorption; however, based on limited systemic exposure, the half-life is estimated to be less than 2 hours. |
| Protein binding | Due to minimal systemic absorption, protein binding data are not clinically relevant. In vitro studies suggest binding to albumin and other plasma proteins is >90%. |
| Volume of Distribution | Vd cannot be reliably calculated due to negligible systemic absorption; estimated to be low (<0.1 L/kg) based on physicochemical properties. |
| Bioavailability | Bioavailability is negligible (<0.1%) after topical application; systemic absorption is minimal. |
| Onset of Action | Clinical effect (clearance of external genital and perianal warts) typically observed after 4-8 weeks of thrice-daily application. |
| Duration of Action | Duration of action is not well-defined; treatment continues until complete clearance of warts, usually up to 16 weeks. Recurrence rates are variable. |
Topical application of 15% ointment to external genital and perianal warts three times daily (every 8 hours) for up to 16 weeks.
| Dosage form | OINTMENT |
| Renal impairment | No dosage adjustment required for any degree of renal impairment. |
| Liver impairment | No dosage adjustment required for any degree of hepatic impairment. |
| Pediatric use | Safety and efficacy not established in pediatric patients under 18 years of age. |
| Geriatric use | No specific dosage adjustment recommended; use with caution due to higher frequency of concomitant conditions and medications. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for VEREGEN (VEREGEN).
| Breastfeeding | It is not known whether sinecatechins are excreted in human milk following topical application. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from sinecatechins, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. The M/P ratio is unknown. |
| Teratogenic Risk | Veregen (sinecatechins) is a botanical drug product indicated for topical treatment of external genital and perianal warts. Systemic absorption is minimal following topical application. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted with sinecatechins. Based on negligible systemic absorption, the risk of fetal harm is considered low, but it should be used during pregnancy only if clearly needed. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to any component of the product"]
| Precautions | ["Not for use on mucous membranes (e.g., vaginal, cervical, oral, or urethral warts)","Avoid application to open wounds or inflamed skin","Sexual contact should be avoided while ointment is on the skin","May weaken condoms and diaphragms; avoid concurrent use during treatment","Use in patients with compromised skin immunity has not been studied"] |
Loading safety data…
| Fetal Monitoring | No specific maternal or fetal monitoring is required beyond usual prenatal care. If applied to genital area during pregnancy, observe for local reactions. Systemic effects are unlikely due to minimal absorption. |
| Fertility Effects | No studies have been conducted on the effects of sinecatechins on fertility. Based on the minimal systemic absorption, effects on fertility are unlikely. |